compression fractures in Spain. METHODS: Two alternative models will be introduced here. One standard contingent valuation model (CV), where mean values for willingness to pay (WTP) for the treatment with BKP are obtained through a survey including patients with primary osteoporosis. A new quality of life adjusted wages model (QAW) is also introduced here. The main assumption of this model is that a disease acts on individuals as a tax, where wages are deflected here by a quality of life index in the same way as a proportional income tax. The burden of disease is given by this model in terms of an equivalent variation or welfare changes in monetary terms. The model avoids different kind of biases introduced in many times by the CV approach and is a faster and more rigorous tool to find welfare changes determined by diseases and their medical treatments. RESULTS: A sample of 168 individuals who had been asked about their WTP for BKP was used to develop the CV model. A mean value for WTP of €3909 is revealed by the sample. A sample of 300 patients 21 years of age or older and both genders coming from a clinical trial designed by Kyphon, was used to develop QAW model, here is that BKP determines in the first month a yearly welfare gain of €2665, increased to €3311 after 12 months. CONCLUSIONS: The results using CV models and QAW model are similar in the first year of life. It can be explained through a temporal downward bias introduced by WTP responses that means that a patient doesn't include in his personal WTP an estimation of his life expectancy. Pfizer GmbH, Karlsruhe, Germany OBJECTIVES: Evidence-based guidelines recommend treatment for postmenopausal women with osteoporosis to prevent fractures. The study aims at determining since when this was known and whether the utilization of bisphosphonates in Germany from this point onward was adequate and to what extent health gains might have been foregone due to a limited use of bisphosphonates. METHODS: To determine since when the beneficial effect (prevention of fractures) was known, cumulative meta-analyses of randomized controlled trials derived from systematic reviews were conducted. The evidence-base was considered as established, when a significant (5%-level) reduction of fractures was observed in trial populations combined in meta-analysis compared to therapies without bisphosphonates. Utilization figures for bisphosphonates and epidemiological estimates where taken from published sources. RESULTS: The hip/femur fracture risk was significantly lower if treatment included bisphosphonates compared to treatment without bisphosphonates (RR 0.62; 95%-CI 0.40-0.97 / RR 0.45; 95%-CI 0.23-0.90). In principal, this was known since 1995/1996. Utilization of bisphosphonates in 1996 was sufficient for the continuous treatment of about 8,200 patients (440,000 patients in 2006). About 1.6 to 1.9 million patients annually might have benefitted from treatment. About 22,800 fractures might thus have been avoided, had all patients with potential benefit continuously received bisphosphonates since 1996/1997. CON-CLUSIONS: The delay in the wider use of bisphosphonates for osteoporosis treatment has resulted in a considerable loss of potential health gains in terms of avoided fractures. An arguable lack of evidence for the expected benefit from bisphosphonate therapy does not sufficiently explain this finding. Other factors (e.g. cost considerations) might have contributed to this result. Limitations of the present analysis are primarily associated with uncertainties of epidemiological estimates and the application of study results to the entire patient population. response to Ն2 DMARDs including methotrexate, no prior bDMARDs) were assessed at three-month intervals for 48 months. Dosing was determined by the attending rheumatologist guided by the recommended labelled doses (adalimumab 40 mg every other week, etanercept 25 mg twice weekly, infliximab 3 mg/kg at week 0, 2, 4, 8 and every 8 weeks thereafter). Mean dose was calculated based on the actual dose prescribed at each visit and the change over time evaluated for each anti-TNFa. RESULTS: The mean baseline doses for adalimumab (N = 374), etanercept (N = 432) and infliximab (N = 325) were 39.9 mg/two weeks, 24.2 mg twice weekly, and 3.4 mg/kg per eight weeks. Mean baseline DAS28 and HAQ ranged from 5.2-5.4 and 1.3-1.4, respectively. Nearly one-third of infliximab patients were prescribed greater than the labelled dose at baseline (32%, N = 105) compared to 2.5% and 0.2% for adalimumab and etanercept. At 12, 24, and 48 months follow-up, mean doses were: adalimumab, 41.5, 43.3, and 45.7 mg/two weeks (42 months); etanercept, 24.0, 24.9, and 23.9 mg twice per week (45 months); infliximab, 4.3, 4.9, and 4.9 mg/kg/every eight weeks (48 months). Mean doses in infliximab patients prescribed greater than the recommended labelled dose at baseline were 4.7, 5.2, and 5.6 mg/kg at the same follow-up intervals. CONCLUSIONS: Longitudinal patient registry data from The Netherlands show a marked and continued dose escalation in RA patients prescribed infliximab as a first-line anti-TNFa when compared to either adalimumab or etanercept.
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PMS68 ANTI-TUMOUR NECROSIS FACTOR-&ALPHA; INHIBITOR DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN
PMS69 PATTERNS OF MORBIDITY AND DIRECT COSTS ASSOCIATED IN THE OSTEOPOROSIS SPANISH POPULATION SETTING
Sicras A 1 , Navarro R 1 , Rejas J 2 1 Badalona Servicios Asistenciales, Barcelona, Spain, 2 Pfizer Spain, Madrid, Spain OBJECTIVES: To determine the co-morbidity and direct cost influence in patients with osteoporosis in a Spanish population setting in under usual medical practice. METHODS: We performed a transversal retrospective study realized beginning from registers of subjects older than Ն44 years appertaining to seven centers of primary care (year 2,006). A control group without osteoporosis was formed. Main measures: general (age, gender), general co-morbidities and specific (ICPC-2), Charlson index (patient severity), biochemical parameters (lipids, glucose, etc.) and cost model. The general morbidity charge was quantified beginning from Adjusted Clinical Groups (http://www.acg. jhph.edu). The program provides the utilization bands of resources (RUB, co-morbidities levels). It was considered fixed/ semi-fixed cost structure/salary/services) and variable one (diagnostics/therapeutical requests, referrals, drugs). Logistical regression analysis was effected (procedure: enter) and the covariance (ANCOVA) for the correction of the models (procedure: Bonferroni), according to the recommendations of ThompsonBarber. Program SPSSWIN; p < 0.05. RESULTS: A total of 35,207 subjects Ն44 years were studied, 10.9% (95% CI: 13.3-15.1%) show osteoporosis (average aged: 62.5 Ϯ 11.8 years; woman: 94.4%). The patients with osteoporosis presented main general morbidity (RUB: 2.9 Ϯ 0.6 vs. 2.7 Ϯ 0.7; episodes: 8.0 Ϯ 4.5 vs. 5.7 Ϯ 3.7), total cholesterol (213.2 Ϯ 36.1 vs. 208.9 Ϯ 30.9 mg/ml), visits (12.9 Ϯ 10.9 vs. 9.6 Ϯ 9.3) and polypharmacy (41.2% vs. 22.2%), p < 0.001. The osteoporosis had an independent association in presence from fracture (OR = 1.4), fibromyalgia (OR = 1.3), dyslipidemia (OR = 1.3), asthma (OR = 1.2), depression (OR = 1.2) y thyroid diseases (OR = 1.2), p < 0.001. The average unitary/total cost adjusted for year, gender and RUB was €1387.28 vs. €808.98; and the pharmaceutical of €1018.62 vs. €522.33; p < 0.001. All components of outpatient management costs were significantly higher in the osteoporosis group. Eighteen percent of the total cost was related to drugs. CONCLUSIONS: Patients with osteoporosis presented a high morbidity (general) and specific one, existing differences of gender (women), producing a high consume of sanitary recourses.
POSTER SESSION III CONCEPTUAL PAPERS & RESEARCH ON METHODS-Clinical Outcomes Methods
PMC1 COLLECTING REAL DATA FROM REAL PATIENTS
Wade AG, Crawford G Patients Direct, Glasgow, UK OBJECTIVES: 1) To assess the willingness of patients to provide information about medical treatment, and 2) to practically demonstrate that useful information can be collected METHODS: Public acceptability towards reporting side-effects and efficacy of medical treatments was assessed by 1) online questionnaire, and 2) assisted questionnaire. Results from the first 137 respondents to the on-line questionnaire and 115 respondents to the assisted questionnaire are reported. A total of 110 leaflets were distributed inviting patients to log on to a dedicated website and provide information on post-vaccination symptoms. Information was gathered on the day of vaccination, two days later and at day eight. RESULTS: A total of 94% of interviewees were aware of the possibility of side effects. Of interviewees who had personal experience of side effects, 39% did not report them. The perceived principle conduit (81%) for reporting was to the physician. The motivating factors for reporting adverse drug reactions (ADR's) in order of frequency was stated to be, ensuring medical safety of others (31%), ensuring their own future good health (28%) the advice of pharmacists/nurses (12%) and financial incentives if available (7%). A total of 73% reported willingness to report side-effects via the Internet. A total of 110 leaflets were distributed at an influenza vaccine clinic inviting patients to log on to an interactive website and provide information. 73 (66%) registered on the day of vaccination, 70 (96%) responded at day two and 66 (90%) at day eight. Statistics on pain and discomfort demonstrate that while the majority of patients have no pain, 8% experienced significant discomfort and 3% pain for greater than one hour. Of side effects reported, none required medical attention and the majority were self-limiting. CON-CLUSIONS: We have confirmed that patients are willing to provide information about medical treatment via an interactive web-based system. This technique has potential for the conduct of naturalistic studies and for post-marketing surveillance. When conducting systematic reviews of randomised controlled trials (RCTs), an important step is to critically assess the quality of included studies. As emphasis on sound trial design has increased over the years, we sought to establish how quality of studies included in systematic reviews is associated with the publication year of those studies. METHODS: We analysed the studies included in 4 large, clinical systematic reviews of randomised controlled trials conducted by Heron in the last 6 months. These covered 4 disease areas: oncology, hyperlipidaemia, anaesthesia, and serious bacterial infection. The data extracted included a critical appraisal of study quality based on means of quality scales. These were the Jadad scale, which assesses randomisation, blinding, patient attrition and reporting quality and gives a score from 1 (low) to 5 (high), and the allocation concealment grade, which assess whether allocation to treatment was adequately concealed. We analysed trends in both Jadad score and allocation concealment grade by year of publication, with stratification by disease area. RESULTS: A total of 291 trials were included in the analyses from the 4 reviews. Most of these were carried out between 1981-2008. The average overall Jadad score was 2.3, suggesting low overall trial quality. Jadad score increased from a mean of 1.4 over the period 1981-1986 to 2.9 over the period [2001] [2002] [2003] [2004] [2005] [2006] . Furthermore there was an increase in the percentage of high quality (Jadad score 4-5) trials-from 6% in 1981-1986 to 36% in 2001-2006 . Only 3% of RCTs from the period 1981-1990 recorded adequate allocation concealment; this increased to 26% over the period 1996-2006. CONCLUSIONS: There was an observable increase in trial quality over the period analysed. However, the mean Jadad score, and the proportion of trials with adequate concealment of allocation remained low, even by 2006, indicating the need for continued attention to study quality.
PMC2 HAS THE QUALITY OF RANDOMISED CONTROLLED TRIALS
PMC3 OVERCOMING THE FINAL HURDLE: COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG
Shannon PR, Beard S RTI Health Solutions, Manchester, UK OBJECTIVES: Although effective post-approval communication is vital in building awareness in the clinical community of newly approved and recommended drugs, the development of such communications can often have a lower priority than supporting a drug through its formal regulatory submission. In this study we considered how standard Excel-based cost effectiveness models could be adapted to enhance communication of economic value. METHODS: Even with a clear and positive regulatory approval and recommendation, from groups such as National Institute for Health and Clinical Excellence (NICE), an additional hurdle is
